Human methylome studies SRP115074 Track Settings
 
Lack of Repressive Capacity of Human Promoter DNA Methylation identified through Genome-Wide Epigenomic Manipulation [Brest Cancer Cell Line]

Track collection: Human methylome studies

+  All tracks in this collection (438)

Maximum display mode:       Reset to defaults   
Select views (Help):
AMR       CpG reads ▾       PMD       CpG methylation ▾      
Select subtracks by views and experiment:
 All views AMR  CpG reads  PMD  CpG methylation 
experiment
SRX3075707 
SRX3075708 
SRX3075709 
SRX3075710 
SRX3075711 
SRX3075712 
SRX3075713 
SRX3075714 
SRX3075715 
SRX3075716 
List subtracks: only selected/visible    all    ()
  experiment↓1 views↓2   Track Name↓3  
hide
 Configure
 SRX3075707  CpG methylation  Brest Cancer Cell Line / SRX3075707 (CpG methylation)   Data format 
hide
 Configure
 SRX3075708  CpG methylation  Brest Cancer Cell Line / SRX3075708 (CpG methylation)   Data format 
hide
 Configure
 SRX3075709  CpG methylation  Brest Cancer Cell Line / SRX3075709 (CpG methylation)   Data format 
hide
 Configure
 SRX3075710  CpG methylation  Brest Cancer Cell Line / SRX3075710 (CpG methylation)   Data format 
hide
 Configure
 SRX3075711  CpG methylation  Brest Cancer Cell Line / SRX3075711 (CpG methylation)   Data format 
hide
 Configure
 SRX3075712  CpG methylation  Brest Cancer Cell Line / SRX3075712 (CpG methylation)   Data format 
hide
 Configure
 SRX3075713  CpG methylation  Brest Cancer Cell Line / SRX3075713 (CpG methylation)   Data format 
hide
 Configure
 SRX3075714  CpG methylation  Brest Cancer Cell Line / SRX3075714 (CpG methylation)   Data format 
hide
 Configure
 SRX3075715  CpG methylation  Brest Cancer Cell Line / SRX3075715 (CpG methylation)   Data format 
hide
 Configure
 SRX3075716  CpG methylation  Brest Cancer Cell Line / SRX3075716 (CpG methylation)   Data format 
    
Assembly: Human Dec. 2013 (GRCh38/hg38)

Study title: Lack of Repressive Capacity of Human Promoter DNA Methylation identified through Genome-Wide Epigenomic Manipulation
SRA: SRP115074
GEO: GSE102395
Pubmed: 35883107

Experiment Label Methylation Coverage HMRs HMR size AMRs AMR size PMDs PMD size Conversion Title
SRX3075707 Brest Cancer Cell Line 0.628 10.4 87083 8814.9 189 968.2 4006 205994.0 0.995 GSM2735962: MCF7_emptyVector_doxInduced_rep1_WGBS; Homo sapiens; Bisulfite-Seq
SRX3075708 Brest Cancer Cell Line 0.633 10.5 79470 8752.3 75 1023.9 4019 185854.2 0.996 GSM2735963: MCF7_empytVector_doxWithdrawn_rep1_WGBS; Homo sapiens; Bisulfite-Seq
SRX3075709 Brest Cancer Cell Line 0.661 13.5 73306 10353.2 140 941.3 3717 211373.0 0.994 GSM2735964: MCF7_ZF_DNMT3A_doxInduced_rep1_WGBS; Homo sapiens; Bisulfite-Seq
SRX3075710 Brest Cancer Cell Line 0.715 8.6 67350 9532.5 84 1004.2 2562 279543.9 0.996 GSM2735965: MCF7_ZF_DNMT3A_doxInduced_rep2_WGBS; Homo sapiens; Bisulfite-Seq
SRX3075711 Brest Cancer Cell Line 0.635 5.3 53591 11916.0 21 1036.9 1773 389058.5 0.999 GSM2735966: MCF7_ZF_DNMT3A_doxInduced_rep3_WGBS; Homo sapiens; Bisulfite-Seq
SRX3075712 Brest Cancer Cell Line 0.688 10.9 76277 8398.6 92 1000.0 3959 181145.2 0.996 GSM2735967: MCF7_ZF_DNMT3A_doxWithdrawn_rep1_WGBS; Homo sapiens; Bisulfite-Seq
SRX3075713 Brest Cancer Cell Line 0.578 3.1 46727 12896.3 6 1364.0 1371 516587.5 0.995 GSM2735968: MCF7_ZF_DNMT3A_doxWithdrawn_rep2_WGBS; Homo sapiens; Bisulfite-Seq
SRX3075714 Brest Cancer Cell Line 0.627 5.3 61936 10222.9 36 1100.7 1958 353515.8 0.999 GSM2735969: MCF7_ZF_DNMT3A_noDox_rep1_WGBS; Homo sapiens; Bisulfite-Seq
SRX3075715 Brest Cancer Cell Line 0.013 4.6 3 1938043.0 4 995.8 11 46000700.1 0.996 GSM2735970: MCF7_emptyVector_doxInduced_TABseq; Homo sapiens; Bisulfite-Seq
SRX3075716 Brest Cancer Cell Line 0.013 15.9 16 825969.8 29 816.9 7 17307324.3 0.996 GSM2735971: MCF7_ZF_DNMT3A_doxInduced_TABseq; Homo sapiens; Bisulfite-Seq

Methods

All analysis was done using a bisulfite sequnecing data analysis pipeline DNMTools developed in the Smith lab at USC.

Mapping reads from bisulfite sequencing: Bisulfite treated reads are mapped to the genomes with the abismal program. Input reads are filtered by their quality, and adapter sequences in the 3' end of reads are trimmed. This is done with cutadapt. Uniquely mapped reads with mismatches/indels below given threshold are retained. For pair-end reads, if the two mates overlap, the overlapping part of the mate with lower quality is discarded. After mapping, we use the format command in dnmtools to merge mates for paired-end reads. We use the dnmtools uniq command to randomly select one from multiple reads mapped exactly to the same location. Without random oligos as UMIs, this is our best indication of PCR duplicates.

Estimating methylation levels: After reads are mapped and filtered, the dnmtools counts command is used to obtain read coverage and estimate methylation levels at individual cytosine sites. We count the number of methylated reads (those containing a C) and the number of unmethylated reads (those containing a T) at each nucleotide in a mapped read that corresponds to a cytosine in the reference genome. The methylation level of that cytosine is estimated as the ratio of methylated to total reads covering that cytosine. For cytosines in the symmetric CpG sequence context, reads from the both strands are collapsed to give a single estimate. Very rarely do the levels differ between strands (typically only if there has been a substitution, as in a somatic mutation), and this approach gives a better estimate.

Bisulfite conversion rate: The bisulfite conversion rate for an experiment is estimated with the dnmtools bsrate command, which computes the fraction of successfully converted nucleotides in reads (those read out as Ts) among all nucleotides in the reads mapped that map over cytosines in the reference genome. This is done either using a spike-in (e.g., lambda), the mitochondrial DNA, or the nuclear genome. In the latter case, only non-CpG sites are used. While this latter approach can be impacted by non-CpG cytosine methylation, in practice it never amounts to much.

Identifying hypomethylated regions (HMRs): In most mammalian cells, the majority of the genome has high methylation, and regions of low methylation are typically the interesting features. (This seems to be true for essentially all healthy differentiated cell types, but not cells of very early embryogenesis, various germ cells and precursors, and placental lineage cells.) These are valleys of low methylation are called hypomethylated regions (HMR) for historical reasons. To identify the HMRs, we use the dnmtools hmr command, which uses a statistical model that accounts for both the methylation level fluctations and the varying amounts of data available at each CpG site.

Partially methylated domains: Partially methylated domains are large genomic regions showing partial methylation observed in immortalized cell lines and cancerous cells. The pmd program is used to identify PMDs.

Allele-specific methylation: Allele-Specific methylated regions refers to regions where the parental allele is differentially methylated compared to the maternal allele. The program allelic is used to compute allele-specific methylation score can be computed for each CpG site by testing the linkage between methylation status of adjacent reads, and the program amrfinder is used to identify regions with allele-specific methylation.

For more detailed description of the methods of each step, please refer to the DNMTools documentation.